Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan

Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index of reactivity (IR) HDM tablet during use for up to 4 years in Japan. 538 patients were ev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunotherapy 2023-11, Vol.15 (16), p.1401-1414
Hauptverfasser: Okamoto, Yoshitaka, Kato, Moe, Ishii, Kiyonori, Sato, Yumi, Hata, Tomohisa, Asaka, Yuta
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1414
container_issue 16
container_start_page 1401
container_title Immunotherapy
container_volume 15
creator Okamoto, Yoshitaka
Kato, Moe
Ishii, Kiyonori
Sato, Yumi
Hata, Tomohisa
Asaka, Yuta
description Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index of reactivity (IR) HDM tablet during use for up to 4 years in Japan. 538 patients were evaluable for safety and 383 for effectiveness. Most adverse drug reactions (ADRs) occurred early and were local reactions; 5.6% of 249 total events were reported during years 2 to 4 as new ADRs after the interim analysis. The CAP-RAST score was identified as a potential risk factor for ADRs. The proportion of evaluable patients with severe allergic rhinitis symptoms decreased from 46.4% at baseline (n = 317) to 1.0% at 4 years (n = 104). Patients (n = 16) who discontinued 300 IR HDM tablet due to symptomatic improvement had sustained improvement relative to baseline 1 to 2 years later. Long-term use of the 300 IR HDM tablet is safe and effective. The 300 index of reactivity house dust mite (HDM) sublingual tablet (Actair ) is a treatment option for people with HDM allergy. A Japanese study investigated the safety and effectiveness of the HDM sublingual tablet during its use for up to 4 years. Less than a third of patients (29%) reported adverse effects, mainly itching or irritation in the mouth. The percentage of patients with no allergic rhinitis symptoms increased from 0.3% before treatment to 57.7% after 4 years of use. The percentage of patients who perceived that their allergic rhinitis had improved ‘substantially’ compared with before treatment increased from 22.3% at 6 months to 73.5% at 4 years. Patients who ended treatment with the HDM sublingual tablet because their symptoms had improved continued to perceive benefit 1 to 2 years later. University hospital Medical Information Network (UMIN) Clinical Trials Registry identifier: UMIN000042840. Long-term use of the 300 IR HDM tablet is safe and effective.
doi_str_mv 10.2217/imt-2023-0100
format Article
fullrecord <record><control><sourceid>futurescience_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_imt_2023_0100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_imt_2023_0100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-59315e4544c59f7ad4d4fd4d40e472344e791dca995be20534a9872747ec1f183</originalsourceid><addsrcrecordid>eNp1UMtKBDEQDKLgunr0nh-IJpNks_Emi4-VBcEHeBuymY5G50WSEeY7_GEz7OLNS3U3VBXVhdA5oxdFwdSlbxIpaMEJZZQeoBlTkhIlxPLwb-dvx-gkxk9KF0ItxAz9PBsHacSmrTA4Bzb5b2ghRtw5bDCnFK-f8Ec3RMDVEBNufAIch23t2_fB1DiZbQ3pClcQbfD9JMeCjGACdr7NBJNhjH5v2HcxkcaEL0jZIBuFb_B1bVoL2Lf4wfSmPUVHztQRzvZzjl5vb15W92TzeLdeXW-I5VInIjVnEoQUwkrtlKlEJdwEFIQquBCgNKus0VpuoaCSC6OXqlBCgWWOLfkckZ2vDV2MAVzZB5-zjSWj5dRomRstp0bLqdHM1zu-G9IQ8r8ecuxydzVQeetb-Ef7CwvEfr4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan</title><source>Open Access: PubMed Central</source><creator>Okamoto, Yoshitaka ; Kato, Moe ; Ishii, Kiyonori ; Sato, Yumi ; Hata, Tomohisa ; Asaka, Yuta</creator><creatorcontrib>Okamoto, Yoshitaka ; Kato, Moe ; Ishii, Kiyonori ; Sato, Yumi ; Hata, Tomohisa ; Asaka, Yuta</creatorcontrib><description>Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index of reactivity (IR) HDM tablet during use for up to 4 years in Japan. 538 patients were evaluable for safety and 383 for effectiveness. Most adverse drug reactions (ADRs) occurred early and were local reactions; 5.6% of 249 total events were reported during years 2 to 4 as new ADRs after the interim analysis. The CAP-RAST score was identified as a potential risk factor for ADRs. The proportion of evaluable patients with severe allergic rhinitis symptoms decreased from 46.4% at baseline (n = 317) to 1.0% at 4 years (n = 104). Patients (n = 16) who discontinued 300 IR HDM tablet due to symptomatic improvement had sustained improvement relative to baseline 1 to 2 years later. Long-term use of the 300 IR HDM tablet is safe and effective. The 300 index of reactivity house dust mite (HDM) sublingual tablet (Actair ) is a treatment option for people with HDM allergy. A Japanese study investigated the safety and effectiveness of the HDM sublingual tablet during its use for up to 4 years. Less than a third of patients (29%) reported adverse effects, mainly itching or irritation in the mouth. The percentage of patients with no allergic rhinitis symptoms increased from 0.3% before treatment to 57.7% after 4 years of use. The percentage of patients who perceived that their allergic rhinitis had improved ‘substantially’ compared with before treatment increased from 22.3% at 6 months to 73.5% at 4 years. Patients who ended treatment with the HDM sublingual tablet because their symptoms had improved continued to perceive benefit 1 to 2 years later. University hospital Medical Information Network (UMIN) Clinical Trials Registry identifier: UMIN000042840. Long-term use of the 300 IR HDM tablet is safe and effective.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2023-0100</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>Actair ; allergic rhinitis ; effectiveness and safety ; house dust mite ; post-marketing survey ; sublingual immunotherapy tablet</subject><ispartof>Immunotherapy, 2023-11, Vol.15 (16), p.1401-1414</ispartof><rights>2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-59315e4544c59f7ad4d4fd4d40e472344e791dca995be20534a9872747ec1f183</citedby><cites>FETCH-LOGICAL-c359t-59315e4544c59f7ad4d4fd4d40e472344e791dca995be20534a9872747ec1f183</cites><orcidid>0000-0001-9352-1582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Okamoto, Yoshitaka</creatorcontrib><creatorcontrib>Kato, Moe</creatorcontrib><creatorcontrib>Ishii, Kiyonori</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Hata, Tomohisa</creatorcontrib><creatorcontrib>Asaka, Yuta</creatorcontrib><title>Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan</title><title>Immunotherapy</title><description>Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index of reactivity (IR) HDM tablet during use for up to 4 years in Japan. 538 patients were evaluable for safety and 383 for effectiveness. Most adverse drug reactions (ADRs) occurred early and were local reactions; 5.6% of 249 total events were reported during years 2 to 4 as new ADRs after the interim analysis. The CAP-RAST score was identified as a potential risk factor for ADRs. The proportion of evaluable patients with severe allergic rhinitis symptoms decreased from 46.4% at baseline (n = 317) to 1.0% at 4 years (n = 104). Patients (n = 16) who discontinued 300 IR HDM tablet due to symptomatic improvement had sustained improvement relative to baseline 1 to 2 years later. Long-term use of the 300 IR HDM tablet is safe and effective. The 300 index of reactivity house dust mite (HDM) sublingual tablet (Actair ) is a treatment option for people with HDM allergy. A Japanese study investigated the safety and effectiveness of the HDM sublingual tablet during its use for up to 4 years. Less than a third of patients (29%) reported adverse effects, mainly itching or irritation in the mouth. The percentage of patients with no allergic rhinitis symptoms increased from 0.3% before treatment to 57.7% after 4 years of use. The percentage of patients who perceived that their allergic rhinitis had improved ‘substantially’ compared with before treatment increased from 22.3% at 6 months to 73.5% at 4 years. Patients who ended treatment with the HDM sublingual tablet because their symptoms had improved continued to perceive benefit 1 to 2 years later. University hospital Medical Information Network (UMIN) Clinical Trials Registry identifier: UMIN000042840. Long-term use of the 300 IR HDM tablet is safe and effective.</description><subject>Actair</subject><subject>allergic rhinitis</subject><subject>effectiveness and safety</subject><subject>house dust mite</subject><subject>post-marketing survey</subject><subject>sublingual immunotherapy tablet</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1UMtKBDEQDKLgunr0nh-IJpNks_Emi4-VBcEHeBuymY5G50WSEeY7_GEz7OLNS3U3VBXVhdA5oxdFwdSlbxIpaMEJZZQeoBlTkhIlxPLwb-dvx-gkxk9KF0ItxAz9PBsHacSmrTA4Bzb5b2ghRtw5bDCnFK-f8Ec3RMDVEBNufAIch23t2_fB1DiZbQ3pClcQbfD9JMeCjGACdr7NBJNhjH5v2HcxkcaEL0jZIBuFb_B1bVoL2Lf4wfSmPUVHztQRzvZzjl5vb15W92TzeLdeXW-I5VInIjVnEoQUwkrtlKlEJdwEFIQquBCgNKus0VpuoaCSC6OXqlBCgWWOLfkckZ2vDV2MAVzZB5-zjSWj5dRomRstp0bLqdHM1zu-G9IQ8r8ecuxydzVQeetb-Ef7CwvEfr4</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Okamoto, Yoshitaka</creator><creator>Kato, Moe</creator><creator>Ishii, Kiyonori</creator><creator>Sato, Yumi</creator><creator>Hata, Tomohisa</creator><creator>Asaka, Yuta</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-9352-1582</orcidid></search><sort><creationdate>20231101</creationdate><title>Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan</title><author>Okamoto, Yoshitaka ; Kato, Moe ; Ishii, Kiyonori ; Sato, Yumi ; Hata, Tomohisa ; Asaka, Yuta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-59315e4544c59f7ad4d4fd4d40e472344e791dca995be20534a9872747ec1f183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Actair</topic><topic>allergic rhinitis</topic><topic>effectiveness and safety</topic><topic>house dust mite</topic><topic>post-marketing survey</topic><topic>sublingual immunotherapy tablet</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okamoto, Yoshitaka</creatorcontrib><creatorcontrib>Kato, Moe</creatorcontrib><creatorcontrib>Ishii, Kiyonori</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Hata, Tomohisa</creatorcontrib><creatorcontrib>Asaka, Yuta</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>CrossRef</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okamoto, Yoshitaka</au><au>Kato, Moe</au><au>Ishii, Kiyonori</au><au>Sato, Yumi</au><au>Hata, Tomohisa</au><au>Asaka, Yuta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan</atitle><jtitle>Immunotherapy</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>15</volume><issue>16</issue><spage>1401</spage><epage>1414</epage><pages>1401-1414</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index of reactivity (IR) HDM tablet during use for up to 4 years in Japan. 538 patients were evaluable for safety and 383 for effectiveness. Most adverse drug reactions (ADRs) occurred early and were local reactions; 5.6% of 249 total events were reported during years 2 to 4 as new ADRs after the interim analysis. The CAP-RAST score was identified as a potential risk factor for ADRs. The proportion of evaluable patients with severe allergic rhinitis symptoms decreased from 46.4% at baseline (n = 317) to 1.0% at 4 years (n = 104). Patients (n = 16) who discontinued 300 IR HDM tablet due to symptomatic improvement had sustained improvement relative to baseline 1 to 2 years later. Long-term use of the 300 IR HDM tablet is safe and effective. The 300 index of reactivity house dust mite (HDM) sublingual tablet (Actair ) is a treatment option for people with HDM allergy. A Japanese study investigated the safety and effectiveness of the HDM sublingual tablet during its use for up to 4 years. Less than a third of patients (29%) reported adverse effects, mainly itching or irritation in the mouth. The percentage of patients with no allergic rhinitis symptoms increased from 0.3% before treatment to 57.7% after 4 years of use. The percentage of patients who perceived that their allergic rhinitis had improved ‘substantially’ compared with before treatment increased from 22.3% at 6 months to 73.5% at 4 years. Patients who ended treatment with the HDM sublingual tablet because their symptoms had improved continued to perceive benefit 1 to 2 years later. University hospital Medical Information Network (UMIN) Clinical Trials Registry identifier: UMIN000042840. Long-term use of the 300 IR HDM tablet is safe and effective.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/imt-2023-0100</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-9352-1582</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1750-743X
ispartof Immunotherapy, 2023-11, Vol.15 (16), p.1401-1414
issn 1750-743X
1750-7448
language eng
recordid cdi_crossref_primary_10_2217_imt_2023_0100
source Open Access: PubMed Central
subjects Actair
allergic rhinitis
effectiveness and safety
house dust mite
post-marketing survey
sublingual immunotherapy tablet
title Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A54%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20effectiveness%20of%20a%20300%20IR%20house%20dust%20mite%20sublingual%20tablet:%20descriptive%204-year%20final%20analysis%20of%20a%20post-marketing%20surveillance%20in%20Japan&rft.jtitle=Immunotherapy&rft.au=Okamoto,%20Yoshitaka&rft.date=2023-11-01&rft.volume=15&rft.issue=16&rft.spage=1401&rft.epage=1414&rft.pages=1401-1414&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2023-0100&rft_dat=%3Cfuturescience_cross%3E10_2217_imt_2023_0100%3C/futurescience_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true